138 related articles for article (PubMed ID: 22285127)
1. Membranous nephropathy in systemic lupus erythematosus: long-term outcome and prognostic factors of 103 patients.
Moroni G; Quaglini S; Gravellone L; Gallelli B; Leoni A; Messa P; Sinico RA
Semin Arthritis Rheum; 2012 Apr; 41(5):642-51. PubMed ID: 22285127
[TBL] [Abstract][Full Text] [Related]
2. Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine.
Mok CC; Ying KY; Yim CW; Ng WL; Wong WS
Lupus; 2009 Oct; 18(12):1091-5. PubMed ID: 19762384
[TBL] [Abstract][Full Text] [Related]
3. Prednisolone and azathioprine in membranous nephropathy: a 10-year follow-up study.
Goumenos DS; Ahuja M; Davlouros P; El Nahas AM; Brown CB
Clin Nephrol; 2006 May; 65(5):317-23. PubMed ID: 16724651
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors of diffuse proliferative lupus nephritis.
Lim CS; Chin HJ; Jung YC; Kim YS; Ahn C; Han JS; Kim S; Lee JS
Clin Nephrol; 1999 Sep; 52(3):139-47. PubMed ID: 10499308
[TBL] [Abstract][Full Text] [Related]
5. Lupus membranous nephropathy: long-term outcome.
Pasquali S; Banfi G; Zucchelli A; Moroni G; Ponticelli C; Zucchelli P
Clin Nephrol; 1993 Apr; 39(4):175-82. PubMed ID: 8491046
[TBL] [Abstract][Full Text] [Related]
6. The prognosis of biopsy-proven lupus nephritis in chinese patients: long term follow-up of 86 cases.
Shen K; Yu Y; Tang Z; Liu Z; Li L
Chin Med J (Engl); 1997 Jul; 110(7):502-7. PubMed ID: 9594205
[TBL] [Abstract][Full Text] [Related]
7. Clinical and morphological prognostic factors in membranous nephropathy: significance of focal segmental glomerulosclerosis.
Dumoulin A; Hill GS; Montseny JJ; Meyrier A
Am J Kidney Dis; 2003 Jan; 41(1):38-48. PubMed ID: 12500220
[TBL] [Abstract][Full Text] [Related]
8. Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Study Group.
Branten AJ; Wetzels JF
Clin Nephrol; 2001 Jul; 56(1):1-9. PubMed ID: 11499653
[TBL] [Abstract][Full Text] [Related]
9. [Clinical course and prognostic factors in lupus nephropathy].
Gamba G; Quintanilla L; del Bosque MD; Chew-Wong A; Correa-Rotter R
Rev Invest Clin; 2000; 52(4):397-405. PubMed ID: 11061101
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive treatment of the glomerulonephritis of systemic lupus.
Faedda R; Palomba D; Satta A; Pirisi M; Tanda F; Bartoli E
Clin Nephrol; 1995 Dec; 44(6):367-75. PubMed ID: 8719548
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate.
du Buf-Vereijken PW; Branten AJ; Wetzels JF;
Nephrol Dial Transplant; 2004 May; 19(5):1142-8. PubMed ID: 14993502
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of acute systemic lupus erythematosus with intravenous infusions of cyclophosphamide. Value and limitations].
De Bandt M; Goycochea MV; Meyer O; Delahousse M; Palazzo E; M'Bappé P; Kahn MF
Ann Med Interne (Paris); 1994; 145(2):75-87. PubMed ID: 8024184
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy.
Ponticelli C; Zucchelli P; Passerini P; Cagnoli L; Cesana B; Pozzi C; Pasquali S; Imbasciati E; Grassi C; Redaelli B
N Engl J Med; 1989 Jan; 320(1):8-13. PubMed ID: 2642605
[TBL] [Abstract][Full Text] [Related]
14. Idiopathic membranous nephropathy and nephrotic syndrome: outcome in the era of evidence-based therapy.
McQuarrie EP; Stirling CM; Geddes CC
Nephrol Dial Transplant; 2012 Jan; 27(1):235-42. PubMed ID: 21558430
[TBL] [Abstract][Full Text] [Related]
15. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
Mok CC; Ying KY; Tang S; Leung CY; Lee KW; Ng WL; Wong RW; Lau CS
Arthritis Rheum; 2004 Aug; 50(8):2559-68. PubMed ID: 15334470
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis.
Arends S; Grootscholten C; Derksen RH; Berger SP; de Sévaux RG; Voskuyl AE; Bijl M; Berden JH;
Ann Rheum Dis; 2012 Jun; 71(6):966-73. PubMed ID: 22128082
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and clinicopathologic findings of antiphospholipid syndrome nephropathy in Thai systemic lupus erythematosus patients who underwent renal biopsies.
Cheunsuchon B; Rungkaew P; Chawanasuntorapoj R; Pattaragarn A; Parichatikanond P
Nephrology (Carlton); 2007 Oct; 12(5):474-80. PubMed ID: 17803471
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity.
du Buf-Vereijken PW; Wetzels JF
Nephrol Dial Transplant; 2004 Aug; 19(8):2036-43. PubMed ID: 15187191
[TBL] [Abstract][Full Text] [Related]
19. Treatment of membranous lupus nephritis.
Moroni G; Maccario M; Banfi G; Quaglini S; Ponticelli C
Am J Kidney Dis; 1998 Apr; 31(4):681-6. PubMed ID: 9531186
[TBL] [Abstract][Full Text] [Related]
20. Progressive improvement of patient and renal survival and reduction of morbidity over time in patients with lupus nephritis (LN) followed for 20 years.
Moroni G; Quaglini S; Gallelli B; Banfi G; Messa P; Ponticelli C
Lupus; 2013 Jul; 22(8):810-8. PubMed ID: 23764764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
